2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13C.04 Is Neoadjuvant Chemoimmunotherapy Better Than Chemotherapy in Patients with Limited-Stage Small Cell Lung Cancer

EP.13C.04 Is Neoadjuvant Chemoimmunotherapy Better Than Chemotherapy in Patients with Limited-Stage Small Cell Lung Cancer

Back to course

Pdf Summary

This retrospective study compares neoadjuvant chemoimmunotherapy with chemotherapy in patients with limited-stage small cell lung cancer (LS-SCLC). It specifically examines the addition of immune checkpoint inhibitors (ICIs) to chemotherapy and their impact on survival, an area previously unexplored in neoadjuvant settings for LS-SCLC.<br /><br />The study analyzed 51 patients, with 26 receiving chemoimmunotherapy and 25 receiving chemotherapy. The average age was 61.6 years for the chemoimmunotherapy group and 59.5 years for the chemotherapy group. The primary endpoints were the pathologic complete response (pCR) and major pathologic response (MPR) rates. Results showed a pCR rate of 38.5% in the chemoimmunotherapy group compared to 8.0% in the chemotherapy group, and an MPR rate of 53.8% versus 12.0%, respectively. <br /><br />Secondary endpoints highlighted a higher R0 resection rate (92.3% vs. 80.0%) and improved pathologic and N2 downstaging rates in the chemoimmunotherapy group compared to the chemotherapy group. After a median follow-up of 17.2 months, the median disease-free survival (DFS) was not reached in the chemoimmunotherapy group but was 11.3 months in the chemotherapy group.<br /><br />The study concludes that neoadjuvant ICIs combined with chemotherapy show promising efficacy and feasibility as a strategy for managing LS-SCLC. It suggests that further prospective randomized controlled trials are needed to confirm benefits and optimize treatment regimens.<br /><br />Overall, the results suggest that chemoimmunotherapy could potentially improve clinical outcomes in LS-SCLC patients by enhancing response rates and disease-free survival compared to chemotherapy alone.

Asset Subtitle

Ting Wang

Meta Tag

Speaker Ting Wang

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

neoadjuvant chemoimmunotherapy

small cell lung cancer

immune checkpoint inhibitors

pathologic complete response

major pathologic response

disease-free survival

R0 resection rate

N2 downstaging

retrospective study

treatment regimens